Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Category: Pharma applications

August 1, 2018 Drug delivery / E-ducation / Environmental / Non-pharma applications / Pharma applications

New books on cyclodextrins

Three new books on various aspects of cyclodextrin research and applications have been recently published. 1. Cyclodextrin Fundamentals, Reactivity and

Continue reading

August 1, 2018 CD as API / Pharma applications

First cannabidiol product approved by FDA as medication

Cannabis has been used for medicinal purposes for thousands of years. Its active compounds produce pharmacological effects throughout the body,

Continue reading

July 31, 2018 CD as API / Pharma applications

HPBCD can cross the Brain-Blood Barrier

Matencio et al. reported in their recent paper that 92.8% of HPBCD administered intrathecally to a child suffering from Niemann

Continue reading

July 25, 2018 Pharma applications / Supramolecular systems

Nanoaggregation on command

ScienceDaily reported on the effect of cyclodextrins as parts of synthetic receptors on the aggregation of proteins, recently published by

Continue reading

July 25, 2018 CD as API / Events / Pharma applications

Annual National Niemann Pick Disease Foundation Conference

Among several lectures useful for the families with member(s) suffering in rare diseases the ongoing clinical trials for NPC patients

Continue reading

Posts navigation

«Previous Posts 1 … 72 73 74

Recent Posts

  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • Waterproof and durable luminescent textiles with HPBCD for marine rescue
  • Small anticancer drug release by light
  • Patent application on reduction of envelope viral particle number in a composition containing cyclodextrin
  • γ-Cyclodextrin/Epigallocatechin-3-gallate Inclusion Complexes as Efficient Antioxidants for Preservation of Shrimp Surimi Products

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (199)
  • CD derivatives (251)
  • Cosmetics and toilettry (21)
  • Drug delivery (416)
  • E-ducation (54)
  • Environmental (76)
  • Events (157)
  • Food (120)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (13)
  • Non-pharma applications (209)
  • Other industrial use (58)
  • Pharma applications (677)
  • Supramolecular systems (25)
  • Uncategorized (41)

Top Posts

  • Lanosterol eye drops for cataract treatment
  • Waterproof and durable luminescent textiles with HPBCD for marine rescue
  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • γ-Cyclodextrin/Epigallocatechin-3-gallate Inclusion Complexes as Efficient Antioxidants for Preservation of Shrimp Surimi Products
  • Small anticancer drug release by light
  • New book: Cyclodextrins - new Perspectives
  • Cyclodextrin Metal-Organic Framework as a Broad-Spectrum Potential Delivery Vehicle for the Gasotransmitters
  • MIT scientists filed patent for HPBCD treatment in Alzheimer's disease
  • Pilocarpine eye drops (Vuity)
  • Current Overview of Cyclodextrin-Based Nanocarriers for Enhanced Antifungal Delivery

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 521 other subscribers
 

Loading Comments...